Dr. Anosh Ahmed Foundation Announces Aid for Texas Flood Victims Through America First Foundation
Standing with Texas
As rising waters displace thousands across the state, Dr. Anosh Ahmed has activated his foundation's emergency response team to work with local authorities and communities hardest hit by the disaster. His support will focus on: Direct financial assistance to families who have lost loved ones
to families who have lost loved ones Shelter and essential supplies for displaced residents
for displaced residents Home rebuilding assistance for uninsured families
for uninsured families Collaboration with churches, community organizations, and first responders to ensure effective outreach
'When Americans suffer, we don't wait — we act,' said Dr. Anosh Ahmed. 'This is not just about recovery. It's about restoring dignity and security for our fellow citizens.'
America First in Action
Founded earlier this year, the Anosh Supports America First Foundation was created to uphold and support the pillars of American strength — the military, law enforcement including members of Department of Justice and ex-FBI agents and their families, first responders, and patriotic communities. Dr. Anosh Ahmed's latest move expands that mission into disaster relief, reinforcing his belief that helping those in need is one of the most American acts of all.
'Being a proud Republican and believer in America First means stepping up when our people need help — not just with words, but with real action,' he added.
Rebuilding Lives, Not Just Structures
Dr. Anosh Ahmed's Texas relief plan includes long-term support beyond the initial recovery. His foundation will: Fund home reconstruction for uninsured families
Provide mental health and grief counseling resources
Support first responders and veterans affected by the disaster
Launch community rebuilding initiatives focused on resilience and preparedness
A special 'Texas Strong: America First Gala' will be hosted by the foundation in Dallas to raise additional funds and awareness.
Supporting Those Who Serve
Dr. Ahmed emphasized that veterans, police officers, and military families will be given priority in the foundation's housing and aid programs. His long-standing appreciation for America's protectors is at the heart of every initiative he undertakes.
'Our heroes in uniform deserve more than just our thanks—they deserve action. This relief effort will ensure they are not left behind,' Dr. Anosh Ahmed stated.
About Dr. Anosh Ahmed
Dr. Anosh Ahmed is a physician, entrepreneur, and Republican philanthropist dedicated to the principles of service, patriotism, and community. Through his Anosh Supports America First Foundation , he works to uplift those who serve and strengthen American communities in times of need.
#anoshAhmed #dranoshahmed #anoshahmedMD #dranoshahmedchicago #anoshahmedofficial #anoshIncfoundation #anoshahmedleadership #anoshahmedbook
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
13 minutes ago
- Business Wire
iBlend™ is Highly Rated in Clinical Trial and Significantly Reduced Cravings for Usual Brand Cigarettes
BUSINESS WIRE)--Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on harm-reduction products being developed under the iBlend™ brand name, released its clinical trial results demonstrating that the Company's patented iBlend™ cigarettes were highly rated for satisfaction on the standardized mCEQ questionnaire and significantly reduced cravings for usual brand cigarettes. All four Cabbacis cigarette types were rated higher for satisfaction on the standardized mCEQ questionnaire than has been previously reported in the literature with other 95 percent reduced-nicotine cigarettes. Share Cabbacis contracted the Rose Research Center to carry out a pilot clinical trial on 16 smokers exclusively using four types of reduced-nicotine tobacco cigarettes made by Cabbacis during 3-hour ad libitum use sessions, which followed overnight abstinence from their usual brand cigarette. The nicotine content of all types was reduced by approximately 95 percent, as compared to the average of mainstream American brands. Three iBlend™ cigarette types contained reduced-nicotine tobacco and each type had a different level of hemp (5%, 10% and 20%), and the fourth cigarette type contained reduced-nicotine tobacco without any hemp. All cigarettes exclusively contained patent-pending tobacco licensed by Cabbacis and grown by its contracted farmers. The study measured the effects of the four cigarette types on smokers' perceptions and smoking behavior. Although other measures in the study were evaluated, the most relevant measures were craving relief and those related to product acceptability. For, Did it immediately reduce your craving for cigarettes, participants across all four cigarette types reported a significant reduction in craving for their usual brand of cigarettes which was sustained over the 3-hours of ad libitum use of the study cigarettes. All four Cabbacis cigarette types were rated higher for satisfaction on the standardized mCEQ questionnaire than has been previously reported in the literature with other 95 percent reduced-nicotine cigarettes. An unexpected positive result of the study was that the use of the three iBlend™ hemp-containing cigarettes (5%, 10% and 20%) resulted in lower exhaled carbon monoxide (CO) levels, as compared to CO levels measured after use of the 0-percent hemp cigarettes, with the reduction in the 20-percent hemp iBlend™ cigarette being statistically significant at the 95 percent confidence level. Dr. Michael Moynihan, Cabbacis's VP of R&D, stated, 'The Company is quite pleased with the results of our initial study which confirmed that reduced-nicotine cigarettes containing hemp are acceptable to tobacco smokers and they significantly reduced cravings for their usual cigarette brand. In order for reduced-nicotine cigarettes to work in terms of reducing smoking and nicotine exposure, smokers must be willing to use them. The data from this study will be useful in designing and carrying out larger iBlend studies of longer duration in the coming months to support our submissions to the U.S. Food and Drug Administration (FDA).' In January 2025, the FDA issued a proposed rule that, if finalized, would make all cigarettes sold in the United States minimally or nonaddictive by limiting the level of nicotine in cigarettes (reduction of ~95%). Upon Cabbacis filing, and FDA issuing a PMTA, commercialization of the reduced-nicotine iBlend™ products would give smokers beneficial product choices with differentiated taste and sensory characteristics to expand the market for reduced-nicotine cigarettes. The FDA has already issued a PMTA and authorized modified-risk product claims on a reduced-nicotine cigarette brand, VLN® (unrelated to Cabbacis), including 'Helps you smoke less®.' In parallel to the FDA process for the U.S. market, the Company is planning to market its products internationally. About Cabbacis Cabbacis is committed to commercializing reduced-nicotine cigarettes and vaporizer pods. Both types of products in development are predominately tobacco and include hemp. The Company also plans to move forward with reduced-nicotine tobacco cigarettes and little cigars without hemp. Reduced-nicotine cigarettes without hemp that contain about 95 percent less nicotine than conventional cigarettes have been evaluated in dozens of independent studies. Results demonstrate, as reviewed in Donny and White 2022 (Int J Drug Policy 99:103436), that subjects smoked fewer cigarettes per day, reduced their nicotine dependence and exposure, doubled their quit attempts, and/or increased their number of smoke-free days. The Company believes including hemp flower in reduced-nicotine cigarettes improves product acceptability for most smokers and may improve effectiveness due to the presence of non-THC cannabinoids. The worldwide patent portfolio of Cabbacis LLC includes 35 issued patents and various pending patent applications across the United States, Europe, China, India, Japan, Indonesia, Russia, South Korea, Canada, Australia, New Zealand, Mexico, Brazil and other countries – where approximately two-thirds of the world's smokers reside. Cabbacis holds 7 U.S. patents. Cabbacis LLC is a wholly-owned subsidiary of Cabbacis Inc. To learn more about Cabbacis, please visit Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements within the meaning of the federal securities law. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as "anticipate," "believe," 'consider,' "continue," "could," "estimate," "expect," 'foresee,' "intend," 'likely,' "may," "objective," "potential," "plan," "predict," "project," "seek," 'should,' "will" and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Factors that could cause actual results to differ materially are described in 'Risk Factors' in our Regulation A Offering Circular filed with the U.S. Securities and Exchange Commission (SEC) and in our Annual Report on Form 1-K for the period ended December 31, 2024 filed with the SEC. We undertake no responsibility to publicly update or revise any forward-looking statement except as required by applicable law. This press release does not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of that state or jurisdiction.
New York Post
31 minutes ago
- New York Post
How many good days do you have a year?
A new national survey revealed that the average American experiences 252 good days each year, but some states are feeling the good vibes more than others. According to the survey of 5,000 Americans, evenly split across all 50 states, residents in Delaware, Georgia, Hawaii, Idaho, and Oregon all reported above-average numbers of good days. Advertisement Florida topped the list with the highest number overall, averaging 276 good days annually, and at the other end of the spectrum, Connecticut, Kentucky, and Vermont reported the fewest good days per year. The annual 'Bowl Half Full' report was conducted by Talker Research on behalf of Icelandic Provisions and examined the habits, mindsets, and routines that shape Americans' daily optimism. From sleep quality to screen time, and meals to morning rituals, it uncovered what fuels a good day — and who's having the most of them. 6 A new national survey revealed that the average American experiences 252 good days each year, but some states are feeling the good vibes more than others. unai – According to the results, people can tell whether or not they'll have a good day by 8:30 a.m., on average. Advertisement Nearly half of Americans (46%) have a good day ritual or routine to make a standard day feel special, and many people's good day routines are all about starting the morning on the right foot, sharing things like, 'I always eat a high-protein breakfast and meditate as much as I can' and 'I try to write a poem in the morning. If I get that right, I've accomplished something good.' Another respondent said, 'I start [the day] with exercise, a good healthy breakfast and a great attitude,' correlating with the survey findings that good days aren't necessarily defined by everything falling into place, but more so by healthy habits and an optimistic mindset. 6 The annual report examined the habits, mindsets, and routines that shape Americans' daily optimism. Icelandic Provisions Food plays an especially important role in good days: Nearly all Americans (93%) agreed that a good day is largely dependent on getting nourishing food throughout. Advertisement Looking closer, respondents said that they need to eat high-protein (47%), low-sugar (31%), and nutrient-rich foods (28%) for their day to be considered good. And those who have the most good days per year were also found to be some of the most likely to eat high-protein foods such as yogurt, skyr, chicken, and eggs on a typical day. The most popular flavors respondents like to enjoy on a good day are coffee (50%), chocolate (49%), banana (34%), vanilla (30%), caramel (25%), and berry (24%). 6 According to the results, people say they'll know whether they'd have a good day by 8:30 a.m., on average. Chinnapong – Advertisement And according to the findings, good health and nutrition are the No. 1 most important things for a happy life (49%), followed by having strong relationships (48%) and a sense of purpose (48%). The study also found that an optimistic outlook — or seeing the bowl as half full — might be the key to unlocking a good day (51%), with enjoying healthy food (36%), laughing at the little things in life (50%) and quality time with family (50%) scoring high marks as well. 'The data shows that nutrition isn't just about physical health — it's a major player in how we feel emotionally,' added Marissa Karp, registered dietitian, founder of MPM Nutrition, and nutrition consultant to Icelandic Provisions. 'Nutrient-rich foods packed with vitamins, minerals, and protein — like skyr — can give you the steady energy and balance you need to start a good day off strong and keep it going.' 6 For America's optimism score in 2025, the nation gets a 6.5 overall, tallied based on qualities such as determination, perseverance, and patience. Icelandic Provisions Along with uncovering the components of a good day and examining how healthy habits contribute, the survey also compared optimism levels from 2024 to 2025. For America's optimism score in 2025, the nation gets a 6.5 overall, tallied based on qualities such as determination, perseverance, and patience. Although this score is slightly lower than 2024's optimism score, which was 6.7, in the study, when respondents were asked if they identify more with a 'bowl half full' or a 'bowl half empty' mindset, 86% of Americans fell on the optimistic side. These optimistic, 'bowl half full respondents,' were found to be more perseverant, prepared, and positive about their futures, along with having more good days per year than their pessimistic counterparts. Advertisement 6 The study also found that an optimistic outlook might be the key to unlocking a good day, including enjoying healthy food, laughing at the little things in life, and quality time with family. Davide Angelini – 'This year's report reminds us that optimism is more than a mindset — it's a daily practice,' said Mark Alexander, chief executive officer at Icelandic Provisions. 'We set out to explore how optimism has shifted over the past year and how it shapes Americans' ability to have a good day. As Icelandic tradition suggests, optimism isn't just something you feel — it's something you do. At its core, it means setting yourself up for success, especially in health and nutrition.' STATES WITH THE MOST GOOD DAYS PER YEAR No.1: Florida — 276 Advertisement Tied for No. 2: Delaware — 264 Tied for No. 2: Georgia — 264 Tied for No. 2: Hawaii — 264 Tied for No. 2: Idaho — 264 Advertisement Tied for No. 2: Oregon — 264 6 According to the survey, residents in Delaware, Georgia, Hawaii, Idaho, and Oregon all reported above-average numbers of good days. Banana Images – STATES WITH THE LEAST GOOD DAYS PER YEAR Tied for No. 1: Connecticut — 228 Advertisement Tied for No. 1: Kentucky — 228 Tied for No. 1: Vermont — 228 Survey methodology: Talker Research surveyed 5,000 Americans (100 from each state); the survey was commissioned by Icelandic Provisions and administered and conducted online by Talker Research between May 16 and May 27, 2025.
Yahoo
40 minutes ago
- Yahoo
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study
The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg Twice a Week (BIW) and 50% in AML MR with Myelomonocytic/Myelomonoblastic (M4/M5) Subtype Median Overall Survival (mOS) of 8.9 Months in Patients with AML MR and 8.8 mOS in Relapsed or Refractory to Venetoclax-Based Regimens at 30 mg BIW Dose Level Surpasses the Historical Benchmark of 2.4 Months FDA Recommends Advancement towards a Trial Including Newly Diagnosed First-Line AML Patient Cohorts That May Support a New Drug Application; Trial Preparation Underway with Enrollment Expected to Begin by Q1 2026 NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ('SELLAS' or the 'Company'), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that is has met all primary endpoints in its Phase 2 trial of SLS009 (tambiciclib), a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML). The Phase 2 clinical trial of SLS009 is an open-label, single-arm, multi-center study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine at two dose levels, 45 mg and 60 mg. In the 60 mg dose cohort, patients were treated with either a 60 mg dose once per week or a 30 mg dose two times per week. The trial was expanded to include ASXL1-mutated AML patients as well as patients with myelodysplasia-related cytogenetic abnormalities other than ASXL1 mutations. The target response rate for this Phase 2 trial, at the optimal dose level, was at least 20% and a target median survival of at least 3 months. The primary endpoint for the trial was overall response rate (ORR), and key secondary endpoints included overall survival (OS), safety, and tolerability. The trial met all endpoints, demonstrating strong efficacy and favorable safety and tolerability with robust anti-tumor activity. Based on these data, the Company plans to advance SLS009 into a randomized trial that will expand into the newly diagnosed AML populations where earlier intervention may enhance therapeutic outcomes, as well as patients refractory to venetoclax and azacitidine, with the study to support a potential New Drug Application (NDA) with the FDA. 'We are excited to report that our Phase 2 trial met all key endpoints, with clinical responses and survival outcomes that exceed targeted expectations and historical benchmarks,' said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. 'AML remains an area of urgent unmet medical need, particularly for patients with relapsed or refractory disease, where standard treatments are often ineffective and poorly tolerated. What sets SLS009 apart is its consistent efficacy across a broad range of molecular subtypes. The remarkable response rates of 44% among AML MR patients, 50% among ASXL1-mutated AML MR, and 50% among M4/M5 patients at the optimal 30 mg BIW dose far exceed the targeted 20% benchmark. We saw a clear survival benefit with median OS reaching 8.8 months in patients refractory to venetoclax-based regimens in the cohort of patients with median 1 prior line of therapy, surpassing the historical median of 2.4 months and 4.1 months in cohorts with median 2 lines of prior therapy, versus 1.8 months reported in similar patient population. The treatment was also well-tolerated, with no dose-limiting toxicities across any treatment arm, validating both the biological selectivity and safety profile of our approach. We believe these data strongly support the potential of SLS009 to meaningfully extend life in patients with otherwise limited options, and we look forward to sharing these findings in more detail in the future. With the expected Phase 3 REGAL study final analysis by year-end, our galinpepimut-S (GPS) immunotherapy and SLS009 are complementary therapies that together enable us to hopefully address AML patients across the treatment spectrum — from early intervention to maintenance.' Key Phase 2 Results: Patients Characteristics: 54 evaluable r/r AML patients who previously failed venetoclax-based therapies were enrolled and treated with SLS009, and venetoclax/azacitidine; patients were enrolled across all five cohorts. Among the 54 treated patients, 47 had AML MR (87%) and 23 had ASXL1 mutations (43%). 47 out of 54 had AML MR (acute myeloid leukemia with myelodysplasia-related changes). Among AML MR patients,17 had myelomonocytic/myelomonoblastic subtype of AML (M4 and M5), representing 31% of all patients. All patients had adverse risk cytogenetics except one patient who had intermediate risk cytogenetics. The median age of all patients was 69. Median number of prior lines of therapy was 2. Efficacy: The results exceeded the pre-specified ORR threshold of 20%, demonstrating robust clinical activity and supporting advancement into late-stage development. The ORR in all evaluable patients was 33% across all cohorts and dose levels and 40% for the 30mg BIW dose level. At the 30 mg BIW dose, among AML MR patients, the ORR was 44%. The highest efficacy was observed among patients with ASXL1 mutations, with an ORR of 50% (9/18) at 30 mg BIW dose levels and M4/M5 patients with 50% (6/12) ORR. The mOS surpassed the historical benchmark of best available therapy of 2.4 months1 for patients who received one prior line of therapy and 1.8 months for those who received more than one prior line of therapy. The mOS for patients treated with 30mg BIW, with a median of 1 prior line of therapy, was 8.8 months, while the mOS in AML MR patients reached 8.9 months vs. 2.4 months with best available therapy. The mOS for cohorts with a median of 2 prior lines of therapies was 4.1 months vs.1.8 months with best available therapy. Safety: The addition of SLS009 to the venetoclax/azacitidine regimen was well tolerated and did not result in increased toxicities compared to ven/aza alone. No dose-limiting toxicities were observed across all dose levels. Front Line Trial Planning Underway Following FDA Guidance Following a productive end of Phase 2 meeting, the FDA recommended that SELLAS proceeds into a trial to include newly diagnosed, first-line AML patients eligible for venetoclax/azacitidine (aza/ven) therapy, where the agency believes clinical benefit might be greatest. The randomized 80-patient trial is currently in preparation and is expected to begin enrollment by Q1 2026. The trial will include two groups: Predictive biomarker cohort: Newly diagnosed patients unlikely to benefit from standard aza/ven therapy based on molecular profiling Early resistance cohort: Patients who initiate treatment with aza/ven but demonstrate confirmed lack of any response after two treatment cycles This precision approach allows SELLAS to target subpopulations with high unmet need and greatest potential for benefit. 'These SLS009 results represent an important advancement for patients with r/r AML, where treatment options remain limited and outcomes are often poor,' said Dr. Yair Levy, Director of Hematologic Malignancies Research at Texas Oncology Baylor University Medical Center. 'The response rates and survival outcomes are particularly compelling, especially given the consistency of responses across high-risk molecular subtypes and the favorable safety profile. What's especially encouraging is the opportunity to now explore this therapy in the first-line setting, where outcomes are often dictated by how patients respond to initial treatment. The FDA's recognition of this unmet need and its support for a trial in newly diagnosed patients reflects SLS009's potential to address a critical gap in AML care.' 'Following constructive FDA guidance, we are preparing the trial focused on newly diagnosed AML patients as well as those early refractory to venetoclax and azacitidine,' said Dragan Cicic, MD, Chief Development Officer of SELLAS. 'The study will include two groups – one comprising patients predicted not to benefit from standard aza/ven, based on cytogenetic risk factors, and a second comprising patients who begin aza/ven treatment but demonstrate confirmed resistance after two cycles. We believe earlier intervention with SLS009 may offer greater clinical benefit before patients' bone marrow reserve is depleted by disease or prior therapies, and before the disease evolves into more resistant and aggressive forms. Data from other recent clinical trials suggests meaningful differences in response rates between newly diagnosed and relapsed/refractory patients, reinforcing the importance of this strategic approach. In addition, our ongoing collaboration with one of the nation's most prestigious cancer centers continues to generate insights in genomics, proteomics, and transcriptomics, which will refine patient selection and our precision medicine strategy and help us unlock the full potential of SLS009 as we prepare to enter pivotal development.' Zainaldin et al, Leukemia and Lymphoma, 2022 About SELLAS Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as 'plan,' 'expect,' 'anticipate,' 'may,' 'might,' 'will,' 'should,' 'project,' 'believe,' 'estimate,' 'predict,' 'potential,' 'intend,' or 'continue' and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption 'Risk Factors' in SELLAS' Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made. Investor Contact John Fraunces Managing Director LifeSci Advisors, LLC jfraunces@
